This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DENTSPLY SIRONA (XRAY) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q2 revenues are driven by a rise in demand across key markets, especially in China. Improved pricing and restructuring initiatives boost earnings.
NuVasive (NUVA) Q2 Earnings Meet Estimates, Margins Down
by Zacks Equity Research
NuVasive's (NUVA) second-quarter 2023 results reflect the robust performance of the U.S. Cervical business.
CVS Health (CVS) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Pharmacy drug mix, growth in specialty pharmacy, brand inflation and the acquisitions of Oak Street Health and Signify Health drive CVS Health's (CVS) Q2 revenues.
Penumbra (PEN) Q2 Earnings Top Estimates, Sales View Raised
by Zacks Equity Research
Penumbra's (PEN) U.S. thrombectomy records 50% year-over-year growth, while the international Vascular business sees relatively flat sales in the second quarter.
Nevro (NVRO) Q2 Earnings Lag Estimates, FY23 View Cut
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the second quarter owing to robust domestic and international performances.
Inspire Medical (INSP) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the second quarter.
Exact Sciences (EXAS) Beats on Q2 Earnings, Ups '23 Sales View
by Zacks Equity Research
Strength in Screening revenues and Precision Oncology drive Exact Sciences (EXAS) Q2 performance.
AmerisourceBergen (ABC) Beats on Q3 Earnings, Ups '23 EPS View
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.
Revvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS View
by Zacks Equity Research
Revvity's (RVTY) second-quarter results reflect the impact of lower COVID-related sales. Both earnings and sales outpace their respective consensus estimate.
Omnicell (OMCL) Q2 Earnings and Revenues Top, '23 View Raised
by Zacks Equity Research
Omnicell's (OMCL) second-quarter 2023 performance reflects strength in advanced services and technical services as well as continued strong execution.
Tenet Healthcare (THC) Q2 Earnings Beat on Solid Hospital Unit
by Zacks Equity Research
Tenet Healthcare's (THC) Q2 results gain on improved adjusted admissions and higher pricing yield. Management expects adjusted EPS of $5.18-$6.03 for this year.
Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across all segments drives its Q2 sales, despite business challenges.
Hologic's (HOLX) Q3 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
Strength in Breast Health and GYN Surgical drives Hologic's (HOLX) Q3 performance.
IDEXX (IDXX) Q2 Earnings and Revenues Beat Estimates, View Up
by Zacks Equity Research
IDEXX (IDXX) delivers better-than-expected earnings and revenues in the second quarter of 2023, backed by CAG Diagnostics' recurring revenue growth.
Zimmer Biomet (ZBH) Q2 Earnings Match Estimates, View Raised
by Zacks Equity Research
Barring S.E.T., Zimmer Biomet (ZBH) records strong growth across each of its business segments in the second quarter.
Zacks Industry Outlook Highlights Abbott Laboratories, Stryker, Zimmer Biomet and Haemonetics
by Zacks Equity Research
Abbott Laboratories, Stryker, Zimmer Biomet and Haemonetics are part of the Zacks Industry Outlook article.
Avantor (AVTR) Q2 Earnings Lag Estimates, FY23 View Revised
by Zacks Equity Research
Despite Avantor's (AVTR) strength in end markets, it reports an overall soft second-quarter performance.
4 Medical Product Stocks to Buy Amid Recovering Prospects
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. ABT, SYK, ZBH and HAE are well poised to gain from the favorable factors.
Integer Holdings (ITGR) Q2 Earnings Top Estimates, FY23 View Up
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip
by Zacks Equity Research
Strength in Hugh Acuity Care segment and Hospice division drive Amedisys (AMED) Q2 performance.
Integra's (IART) Q2 Earnings Top Estimates, 2023 View Cut
by Zacks Equity Research
In CSS, Integra (IART) registers strong growth owing to high single-digit growth in Advanced Energy and mid-single-digit growth in CSF management during Q2.
DexCom (DXCM) Q2 Earnings Beat Estimates, Volumes Remain Strong
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Neogen (NEOG) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Neogen (NEOG) Q4 fiscal 2023 results reflect core growth in both operating segments despite softening market conditions.
LabCorp (LH) Q2 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
A rise in organic revenues, acquisitions, net of divestitures and foreign currency translation drive LabCorp's (LH) Q2 revenues.
Edwards Lifesciences (EW) Q2 Earnings Top Estimates, View Up
by Zacks Equity Research
The growing adoption of the PASCAL Precision system in Europe and the United States and Edwards' premium products across all regions have driven Edwards Lifesciences' (EW) Q2 revenues.